

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 石四藥集團有限公司 SSY Group Limited

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2005)**

## **VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT**

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce the updates on product development of the Group as follows:

1. The Group has obtained the approval for drug production and registration for Oseltamivir Phosphate Capsules (30mg, 45mg and 75mg) from National Medical Products Administration of China (the “NMPA”), being under type 4 chemical drug and regarded as passing the consistency evaluation. This product is mainly used for the treatment of influenza A and B in adults and children aged 1 year and older, and for the prevention of influenza A and B in adults and adolescents aged 13 years and older.
2. The Group, being the second of the PRC entities, has obtained the approval for drug production and registration for Drotaverine Hydrochloride Tablets (40mg) from the NMPA, being under type 3 and regarded as passing the consistency evaluation. This product is mainly used for smooth muscle spasms related to biliary tract diseases and urinary system diseases, as well as an adjunct treatment for smooth muscle spasms caused by gastrointestinal diseases and for dysmenorrhea. As stated in the Company’s announcement dated 6 August 2025, the Group’s Drotaverine Hydrochloride bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.
3. The Group, being the second of the PRC entities, has obtained the approval for drug production and registration for Metoclopramide Tablets (10mg) from the NMPA, being under type 3 and regarded as passing the consistency evaluation. This product is mainly used for symptomatic treatment of nausea and vomiting caused by various diseases, short term treatment of symptomatic gastroesophageal reflux that is unresponsive to conventional treatment, and relief of symptoms of acute and recurrent diabetic gastroparesis. As stated in the Company’s announcement dated 27 February 2026, the Group’s Metoclopramide bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board  
**Chow Hing Yeung**  
*Executive Director and Company Secretary*

Hong Kong, 11 May 2026

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.*